---
title: "Innovent to Present Multiple Clinical and Preclinical Results of Mazdutide and Next-Generation Obesity & Metabolic Pipeline at the 2026 ADA Scientific Sessions"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/286171995.md"
description: "Innovent Biologics, Inc. will present clinical and preclinical results of mazdutide and its next-generation obesity and metabolic pipeline at the 2026 ADA Scientific Sessions in New Orleans from June 5-8, 2026. Key presentations include studies on mazdutide's efficacy in adults and adolescents with obesity and type 2 diabetes, highlighting its profile as a GCG/GLP-1 dual receptor agonist. The pipeline also features innovative oral GLP-1 receptor agonists and an amylin analog aimed at addressing obesity-related challenges. This event marks a significant step for Innovent in establishing leadership in obesity and metabolic disease treatment."
datetime: "2026-05-13T00:02:38.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/286171995.md)
  - [en](https://longbridge.com/en/news/286171995.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/286171995.md)
---

# Innovent to Present Multiple Clinical and Preclinical Results of Mazdutide and Next-Generation Obesity & Metabolic Pipeline at the 2026 ADA Scientific Sessions

On May 12, 2026, it was announced that Innovent Biologics, Inc. ("Innovent") based in San Francisco and Suzhou, China, is a leading biopharmaceutical company specializing in the development, manufacturing, and distribution of top-tier medications. Innovent is listed on the Hong Kong Stock Exchange under the symbol 01801. The company focuses on producing high-quality drugs for oncology, cardiovascular, and metabolic treatments.

### Related Stocks

- [159892.CN](https://longbridge.com/en/quote/159892.CN.md)
- [589720.CN](https://longbridge.com/en/quote/589720.CN.md)
- [159615.CN](https://longbridge.com/en/quote/159615.CN.md)
- [159849.CN](https://longbridge.com/en/quote/159849.CN.md)
- [588130.CN](https://longbridge.com/en/quote/588130.CN.md)
- [512290.CN](https://longbridge.com/en/quote/512290.CN.md)
- [588250.CN](https://longbridge.com/en/quote/588250.CN.md)
- [159316.CN](https://longbridge.com/en/quote/159316.CN.md)
- [560600.CN](https://longbridge.com/en/quote/560600.CN.md)
- [512010.CN](https://longbridge.com/en/quote/512010.CN.md)
- [516930.CN](https://longbridge.com/en/quote/516930.CN.md)
- [159506.CN](https://longbridge.com/en/quote/159506.CN.md)
- [159992.CN](https://longbridge.com/en/quote/159992.CN.md)
- [159102.CN](https://longbridge.com/en/quote/159102.CN.md)
- [516820.CN](https://longbridge.com/en/quote/516820.CN.md)
- [159859.CN](https://longbridge.com/en/quote/159859.CN.md)
- [520690.CN](https://longbridge.com/en/quote/520690.CN.md)
- [520880.CN](https://longbridge.com/en/quote/520880.CN.md)
- [517110.CN](https://longbridge.com/en/quote/517110.CN.md)
- [588860.CN](https://longbridge.com/en/quote/588860.CN.md)
- [516500.CN](https://longbridge.com/en/quote/516500.CN.md)
- [159837.CN](https://longbridge.com/en/quote/159837.CN.md)
- [510660.CN](https://longbridge.com/en/quote/510660.CN.md)
- [159570.CN](https://longbridge.com/en/quote/159570.CN.md)
- [01801.HK](https://longbridge.com/en/quote/01801.HK.md)

## Related News & Research

- [Ab&B Bio-Tech Starts Early-Stage Trials for High-Yield RSV Vaccine as Trading Remains Suspended](https://longbridge.com/en/news/286268861.md)
- [Zai Lab Q1 2026 Results Highlight Pipeline Momentum and Upcoming China Launches](https://longbridge.com/en/news/285564515.md)
- [CStone Launches Nationwide Supply of Locally Made Pralsetinib as China Sales Surge](https://longbridge.com/en/news/285858047.md)
- [Leads Biolabs R&D Symposium: Platform Synergy and Multi-Mechanism Integration Reshape the Immuno-Oncology Landscape](https://longbridge.com/en/news/285930281.md)
- [HBM Holdings Says Director Probed by CSRC, Sees No Impact on Operations](https://longbridge.com/en/news/286197909.md)